Dr Vincent Muczynski

Dr Vincent Muczynski is a translational scientist with more than 10 years of experience in academic research, working on the development of early-stage novel therapeutics to address unmet medical needs.

Vincent joined NovalGen at the start in 2019, and currently serves as Director of Biology. He leads a research team working to develop the autoregulation technology designed to improve the safety profile of immunotherapies, with a particular focus on establishing proof-of-concept in antibodies and cellular therapies. He is also a Research Fellow from the Cancer Institute at University College London, working with Professor Nathwani to explore the translational potential of immunotherapies using viral vectors as a mean of drug delivery across a range of congenital and acquired disorders.

Before relocating to the UK, Vincent was a post-doctoral researcher at INSERM in France, where he was developing new therapeutic molecules for the treatment of haemophilia A using engineered coagulation factors. Vincent hold a PhD in molecular and cellular genetic from University Paris 11 – Sud.